DESC:TECHNICAL FIELD
[0001] The present invention relates, generally, to medical devices for implanting inside a lumen such as blood vessels or ducts and, particularly but not exclusively, related to stents having provisions for an active agent delivery to treat resistant hypertension by altering the behavior of nerves situated in renal artery.

BACKGROUND
[0002] Resistant hypertension refers to a condition of high blood pressure which is not responding to medication. Renal denervation is a minimally invasive procedure to treat resistant hypertension. This process causes a reduction in the nerve activity, which decreases blood pressure. In this process, a form of energy is transferred to the nerves that causes reduction of sympathetic afferent and efferent activity in the nerves and blood pressure can be decreased.
[0003] Though renal denervation is a minimally invasive procedure, but it has some shortcomings too based on the mode of procedure employed. Commonly used procedures include electromagnetic radiation, ablation through thermal or electric energy etc. However, these cause irreversible and excessive injuries to the efferent (sympathetic) and afferent (sensory) fibers that constitute the renal nerves. This can alter renal function and central hemodynamics. Other possible complications include pseudoaneurysm (a bruise caused by a leaking hole in an artery) and tearing in the renal arteries. Instead of radiation or thermal or electrical energy the application of an active agent, including a chemical compound, pharmaceutical compound or a biological compound, is comparatively safer and can be continuously transferred to lumen, tract or duct for long durations.
[0004] Hence, it is an objective of the invention to provide a medical device, specifically a stent with provisions for active agent release, that provides controlled release of active agent continuously, for at least a defined time period, at target lesion by implanting such device in contact with the target lesion to treat Resistant Hypertension.

SUMMARY OF THE INVENTION
[0005] In one aspect of the present invention, a stent for renal denervation is provided. The outer periphery of the stent comprises a plurality of grooves that comprises a composition having at least a polymer, at least an active agent, optionally a solvent, and optionally, an additive. The active agent and the polymer in the composition are in a ratio of 5:95 to 70:30. The stent is deployed at the target lesion in a lumen. The stent comes in contact with the inner wall of the lumen, tract or duct, adheres. The active agent transfers from the composition stored in the grooves on the outer periphery of the stent to the tissues through absorption and diffusion due to concentration difference. In another aspect, the outer periphery of the stent is covered with a fabric and the fabric comprises the active agent or active agent containing composition.

BRIEF DESCRIPTION OF ACCOMPANYING DRAWINGS
[0006] The detailed description is described with reference to the accompanying figures.
FIG. 1 illustrates a detailed view of a stent with slots on its outer periphery and disposed in an lumen, according to an embodiment of the present invention.
FIG. 1A illustrates a magnified view of a portion of a stent with grooves on its outer periphery, according to an embodiment of the present invention.
FIG. 2 illustrates a detailed view of a stent covered with a mesh and disposed in a lumen, according to another embodiment of the present invention.
FIG. 3 illustrates an accelerated drug release profile of an active agent containing composition (Sirolimus + Poly lactide-co-caprolactone (85/15)) filled in grooves of the stent, according to an embodiment of the present invention.
FIG. 3A illustrates a drug release profile of an active agent containing composition (Sirolimus + Poly lactide-co-caprolactone (85/15)) filled in grooves of the stent, according to an embodiment of the present invention.
FIG. 4 illustrates an accelerated drug release profile of an active agent containing composition (Sirolimus + Poly lactide-co-caprolactone (95/5)) filled in grooves of the stent, according to an embodiment of the present invention.
FIG. 4A illustrates a drug release profile of an active agent containing composition (Sirolimus + Poly lactide-co-caprolactone (95/5)) filled in grooves of the stent, according to an embodiment of the present invention.

DESCRIPTION OF THE INVENTION
[0007] An aspect of the present invention is to address at least the abovementioned problems and/or disadvantages and to provide at least the advantages described below. Wherever possible, the same reference numbers will be used throughout the drawings to refer to the same or the like parts. Wherever possible, corresponding, or similar reference numbers will be used throughout the drawings to refer to the same or corresponding parts.
[0008] Where the term “comprising” is used in the present description and claims, it does not exclude other elements or steps. Where an indefinite or definite article is used when referring to a singular noun, e.g. “a” “an” or “the”, this includes a plural of that noun unless something otherwise is specifically stated. Hence, the term “comprising” should not be interpreted as being restricted to the items listed thereafter; it does not exclude other elements or steps.
[0009] According to an embodiment of the present disclosure, a stent is provided for deployment at a target lesion in a lumen, specifically in an artery, endovascularly. The stent has a plurality of grooves on its frame on outer periphery of the stent. The grooves contain at least an active agent either in pure form or in a compositional form. Hence, the grooves act as active agent storage sites and supply the active agent to the tissues on deployment of the stent in the artery. The stent may be a balloon expandable stent or a self-expandable stent and in either type, the outer periphery of the stent will come in contact with the inner wall of the artery on deployment. The active agent present in the grooves starts transferring to the tissues of the inner wall of the artery on contact and continues the active agent delivery over a period of time. The active agent transfers from the grooves to the artery tissues through absorption and diffusion due to concentration difference. The transferred active agent may be targeted to the entire surface area of the inner wall of the artery or to specific targeted points on the inner wall of the artery or within the wall of the artery. The active agent chemically or biologically reacts with specific nerves, molecules, cells or cell manufacturing matter to eliminate of change them to alter specific symptoms.
[0010] According to an embodiment of the present disclosure, the active agent containing composition in the grooves may be stored in a multiple layered structure. In another embodiment of the present disclosure, the active agent containing composition is a polymeric matrix in which the active agent is dispersed throughout the polymeric matrix. In addition, the polymeric matrix may have more than one active agent as well. The other active agent may be targeted to same symptoms or different symptoms or to treat the aftereffects generated due to mesh deployment or due to action of the active agent. Further, the polymeric matrix may also have additional components to enhance other required properties.
[0011] The active agent containing polymeric matrix comprises a biodegradable polymer or a plurality of different biodegradable polymeric materials. In addition, a solvent may also be used to make the composition. By controlling different structural configurations and ratio of components in the polymeric matrix, the rate of release of the active agent can be controlled and a prolonged active agent delivery is achieved.
[0012] According to another embodiment of the present invention, the outer periphery of the stent is covered with a mesh and the active agent is present in the mesh. The mesh is either entangled with the stent or attached to the outer periphery of the stent through sutures, staples or glue. More specifically, biocompatible or biodegradable adhesive, dissolvable/non-dissolvable stitches, staples, knots or sutures can be used to ensure attachment of the mesh with the stent. The mesh can be a woven sheet or anon-woven sheet wherein the sheet contains the active agent. The non-woven sheet is made of a material selected from polymer, non-polymer, cellulose, lignin, natural rubber, sponge or combinations thereof. The woven sheet is made of a plurality of threads. The threads are polymeric fibers, non-polymeric fibers, metal wires, alloy wires, synthetic fiber, natural fiber, silk, cotton or combinations thereof. In another embodiment, the active agent is adsorbed on the surface of the mesh or absorbed in the mesh or on the threads used to make the woven mesh. In yet another embodiment, a thread, entirely or partially, may be made of the active agent. On deployment of the stent, the outer periphery of the stent will come in contact with the inner wall of the lumen, specifically the artery. The active agent present in the mesh starts transferring to the tissues of the inner wall of the artery on contact and continues over a period of time. The active agent transfers through absorption and diffusion due to concentration difference. The transferred active agent may be targeted to the entire surface area of the inner wall of the artery or to specific targeted points on the inner wall of the artery or within the wall of the artery. The active agent chemically or biologically reacts with specific nerves, molecules, cells or cell manufacturing matter to eliminate of change them to alter specific symptoms.
[0013] According to another embodiment of the present disclosure, active agent present in the mesh or grooves may be in form of transferable micro-needles made of pure active agent or active agent filled polymeric cones.
[0014] According to an embodiment of the present disclosure, the solvent is selected from water, polymeric solvent, non-polymeric solvent, saline, biodegradable polymeric liquid or a mixture thereof.
[0015] According to an embodiment of the present disclosure, the polymeric matrix comprises poly lactide-co-caprolactone and the active agent is sirolimus. The drug to polymer ratio in this polymeric composition is between 5:95 to 70:30. The ratio of lactide moiety to caprolactone moiety in the polymer varies between 70:30 to 95:5. The polymeric matrix is designed to release the active agent in two phases where both the phases have different rates of controlled release and the rate of the active agent release in a first phase is higher than a second phase. Higher release rate of the active agent in the first phase ensures required drug transfer and retention while a slower but sustained release of the active agent in the second phase replenishes the consumed quantity of the active agent over a period of time. The amount of active agent release in the first phase varies from 15 weight percent to 60 weight percent, specifically 20 weight percent to 50 weight percent of the total amount of the drug present in the polymeric matrix.
[0016] Explained below is an exemplary embodiment of the present disclosure. As illustrated in Fig. 1, a stent 100, that is designed to be delivered to a target lesion (not shown) in a lumen 102 using a suitable endovascular catheter (not shown) has a plurality of grooves 106 on its outer periphery 104.
On deployment, the outer periphery 104 of the stent 100 contacts the inner wall of the lumen 102 and the active agent or active agent containing composition present in the grooves 106 also comes in contact of the tissues of the inner wall and starts transferring the active agent from grooves to the inner wall. As illustrated in Fig. 1B, the stent 100 includes an outer periphery 104 defining one or more specifically cut or molded grooves 106. Further, these grooves 106 collectively define one or more reservoirs. These reservoirs may contain same active agent or active agent composition or different active agent or active agent containing composition. The stent 100 defines a cylindrical shape structure. The stent 100 is made up of regular or irregular shaped struts, connectors, helix, rings, or combination thereof. Further, the stent 100 is made of a material selected from metal, non-metal, alloy, polymer, biodegradable, bioresorbable material or a combination of two or more thereof. For example, all deformable, biocompatible metal, metal alloy can be used and include, but are not limited to, Stainless steel, Cobalt alloys, pure Iron, Nickel-Titanium alloys, Tantalum, Niobium, Nickel alloys, Magnesium alloys, Zinc alloys, L605, MP25N, and Nitinol.
[0017] As illustrated in Fig. 2, outer periphery 206 of a stent 200 is covered with a mesh 202 and it is deployable in a lumen 204. The mesh 202 is fabric-like, woven or non-woven, structure that comprises an active agent. Specifically, the mesh 202 is a woven fabric made of polymeric threads and the composition of the threads comprises at least an active agent. On deployment, the mesh 202 contacts the inner wall of the lumen 204 and the active agent or active agent containing composition present in the mesh 202 also comes in contact of the tissues of the inner wall and starts transferring the active agent from mesh to the inner wall. The mesh 202 along with the stent 200 is deployed in the lumen 204 to treat renal denervation in endovascular manner. Specifically, the mesh is a woven, fabric-like sheet made of a plurality of polymeric threads that either have active agent dispersed in the polymer or the active agent is deposited on outer surface of the threads. The weaving of the mesh 202 can be of regular or irregular manner.
[0018] In some embodiments, the polymeric thread may have more than one active agent dispersed or deposited to treat the effects generated due to stent 200 deployment or due to action of nerve-specific active agent. The polymeric thread comprises a single biodegradable polymer or a combination of two or more biodegradable polymeric materials. By controlling different structural properties and ratio of polymeric mixture; the rate of release of the active agent can be controlled and a prolonged active agent delivery is achieved.
[0019] Fig. 3 illustrates an active agent release profile of a sirolimus containing poly lactide-co-caprolactone (85/15) based polymeric matrix placed in the grooves of a stent and the stent is placed in a testing environment (in-vitro). The release medium is a simulated biological fluid. The release profile is studied in accelerated condition for a duration of 24 hours. The release medium for accelerated study is a mixture of phosphate buffer saline, non-ionic surfactant and an organic solvent. The pH of the solution is kept at 7.4 and the release study is studied at 37° C temperature to mimic temperature of a normal human body. The active agent release profile clearly shows two phases of active agent release: the rate of release of the active agent is higher in the first phase (in first hour) then the second phase of slower and sustained release over a total duration of 24 hours. Fig. 3A illustrates an active agent release profile of a sirolimus containing poly lactide-co-caprolactone (85/15) based polymeric matrix placed in the grooves of a stent and the stent is placed in a testing environment (in-vitro). The release medium is porcine serum. The release profile is studied for a duration of three days. Similar to the accelerated study, the active agent release profile clearly shows two phases: the rate of release of the active agent is higher in the first phase (day 1) then the second phase of slower and sustained release over next two days.
[0020] Similarly, Fig. 4 illustrates an active agent release profile of a sirolimus containing poly lactide-co-caprolactone (95/5) based polymeric matrix placed in the grooves of a stent and the stent is placed in a testing environment (in-vitro). The release medium is a simulated biological fluid. The release profile is studied in accelerated condition for a duration of 24 hours. The release medium for accelerated study is a mixture of phosphate buffer saline, non-ionic surfactant and an organic solvent. The pH of the solution is kept at 7.4 and the release study is studied at 37° C temperature to mimic temperature of a normal human body. The active agent release profile clearly shows two phases of active agent release: the rate of release of the active agent is higher in the first phase (in first hour) then the second phase of slower and sustained release over a total duration of 24 hours. Fig. 3A illustrates an active agent release profile of a sirolimus containing poly lactide-co-caprolactone (95/5) based polymeric matrix placed in the grooves of a stent and the stent is placed in a testing environment (in-vitro). The release medium is porcine serum. The release profile is studied for a duration of three days. Similar to the accelerated study, the active agent release profile clearly shows two phases: the rate of release of the active agent is higher in the first phase (day 1) then the second phase of slower and sustained release over next two days.
[0021] According to an embodiment of the present disclosure, the polymer is selected from, but not limited to, biodegradable polymers, non-biodegradable polymers, polymers of L-lactide, Glycolide or combinations thereof, poly(hydroxybutyrate), polyorthoesters, poly anhydrides, poly(glycolic acid), poly(glycolide), poly(L-lactic acid), poly(L-lactide), poly(D-lactic acid), poly(D-lactide), poly(caprolactone), poly(trimethylene carbonate), polyester amide, polyesters, polyolefins, polycarbonates, polyoxymethylenes, polyimides, polyethers, and copolymers and combinations thereof.
[0022] According to an embodiment of the present disclosure, the active agent is selected from, but not limited to, anti-restenosis drugs, Neurolytic agents, Quaternary ammonium salts, Sodium Channel Blockers, Anesthetics, Conductive Fluids, Amino Acids, Amines, Calcium Channel Blockers, Diuretics, Heated fluids e.g. Saline, Hypotonic Fluids, Vasovasorum Constrictors, Neurotransmitter Chemicals, Venom, Sclerosant Agents, Anti-Nerve Growth Agents, Aminosteroids, Neurotoxins, Alcohols, 6-Hydroxydopamine, Acebutolol, Acetic Acid, Acetic Anhydride, Acetyl Chloride, Acetylcholine, Adenosine, Aflatoxins, Ambrisentan, Amiloride, Amiodarone, Amlodipine, Ammonia, Anti-Acetylcholinesterase, Anti-Dopamine Beta-Hydroxylase, Anti-Dopamine Beta-Hydroxylase Immunotoxin (DHIT), Anti-Dopamine Beta-Hydroxylase Saporin (DBH-SAP), Argon, Arsenic, Atenolol, Azitoxin, Benazepril, Benzocaine, Bepridil, Betanidine, Betaxolol, Bisoprolol, Bleomycin, Bosentan, Botulinum toxin, Bretylium Tosylate, BuLi, Bungarotoxin, Bupivacaine, Bupranolol hydrochloride, Butanol, Ca(OH)2, Caffeine, Calciceptin, Calcycludin, Capsaicin, Carbamazepine, Carbon Dioxide, Cardiac Glycoside, Caribodotoxin, Carteolol, Carteolol hydrochloride, Catopril, Cetylcholine, Cevacine, Cevadine, Chloroquine, Chlorotoxin, Clonidine, Conotoxin, Curare, Cymarins, Cytochalasin D, Debrisoquine, Decarbamoyl Saxitoxins, Dibucaine, Digitalis, Digitoxins, Digoxins, Diltiazem, Dimethyl Sulfoxide, Diprophylline, Disopyramide, Dobutamine hydrochloride, Domoic Acids, Dopamine hydrochloride, Doxazosin, Doxycycline, Enalapril, Enalaprilat, Encainide, Epinephrin, Esmolol, Ethanol, Ethanolamine Oleate, Ethyl Acetate, Ethyl Chloroformate, Ethyl Iodide, Ethyl Lactate, Ethyl Nitrate, Ethylene glycol, Everolimus, Felodipine, Fimolol, Flecainide, Fosinopril, Furosemide, Glutamate, Glycerin, Glycerol, Guanabenz, Guanacline, Guanadrel, Guanazodine, Guanethidine, Guanethidine Sulfates, Guanfacine, Guanidinium, Guanoclor, Guanoxabenz, Guanoxan, H2O2, Helium, Hexane, Hydriodic Acid, Hydrobromic Acid, Hydrochloric Acid, Hypertonic Saline, Indoramin, Isobutanol, Isopropanol, Isopropyl Acetate, Isopropyl Iodide, Isoquinoline, Isradipine, K2CO3, Ketanserin, KH, KOH, Labetalol, Lactic Acid, Laureth (Polidocanol), Leptocurare, Lidocaine, Lipiodol, Lisinopril, Losartan, Malonic Acid, Malonyl Chloride, Margatoxin, Maurotoxin, Mecamylamine, Methanol, Methyl Acetate, Methyldopa, Metildigoxin, Metirosine, Metoprolol, Metoprolol tartrate, Mexiletine, Minosteroids, Moexipril, Moricizine, Morrhuate Sodium, Moxonidine, Mycophenolic Acid, N-(2-Chloroethyl)-N-Ethyl-2-Bromobenzylamine (DSP4), Nadolol, NaH, NaHCO3, NaOEt, NaOH, NaSEt, Neosaxitoxins, NH4OH, Nicardipine, Nifedipine, Nimodipine, Nitric Acid, Nitric oxide, Nitrogen, Nitrous Acid, N-Methyl-(R)-Sarsolinol, Octopamine hydrochloride, Oleandrins, Ouabin, Oxalic Acid, Oxprenolol hydrochloride, Oxygen, Oxytetracycline, Pachycurare, Paclitaxel, Pargyline, Penbatolol, Peracetic Acid, Perchloric Acid, Phenol, Phentolamine, Pheoxybenzamine, Phosphoric Acid, Phtx3 (Phoneutria toxin), Pindolol, Polidocanol, Potassium Chloride, Povidone Iodine, Prazosin, Prazosin hydrochloride, Prazosin Plus Polythiazide, Procainamide, Propafenone, Propanol, Propranolol, Propranolol hydrochloride, Propyl Iodide, Proscillaridin, Pyruvic Acid, Quabains, Quinacrine, Quinapril, Quinidine, Quinine, Ramipril, Relmenidine, Rescinnamine, Reserpine, Resiniferatoxin, Saline, Saxitoxins, Sirolimus, MK-0431 (Sitagliptin phosphate), Sitaxentan, slatatoxin, Slototoxin, Sodium Chloride (Salt), Sodium Morrhuate, Sodium Tetradecyl Sulfate, Sotalol, Staurosporines, Sulfuric Acid, Talc, Taxol, Terazosin, Tetanus Toxin, Tetracaine, Tetracycline, Tetraethylammonium, Tetrodotoxin, Tocainide, Trichlormethiazide, Trimazosin, Trimethaphan, Tycatoxin, Ubidecarenon, Urapidil, Urea, Vanilloids, Vanilloylzygadenine, Heftoxin, Verapamils, Veratridine, Veratroylzygadenine with saline solution, Vinblastin, Vincristine, Zotarolimus, Zygacine, ß-carboline derivative, ?-conotoxin, Heparinized Saline, Butorakotoshkin, neuromodulators, botulinum oxide.
[0023] The stent can be placed endovascularly in the lumen, specifically an artery selected from femoral artery, renal artery, superficial femoral artery, popliteal artery, tibial artery, genicular artery, cerebral artery, carotid artery, vertebral artery, subclavian artery, radial artery, brachial artery, axillary artery, coronary artery, peripheral artery, iliac artery, or neuro-arteries. For example, the renal denervation catheter may be used in chemical renal denervation procedure.
[0024] According to an embodiment of the present disclosure, the non-ionic surfactant is selected from, but not limited to, different grades from a surfactant family selected from Tween, Brij, and Triton. The organic solvent is selected from, but not limited to, methanol, ethanol, Allyl alcohol, Ethanolamine, Hexane, Heptane, Cyclohexane, 1-octanol, Pentane, Xylene Acetone, Acetonitrile, Tetrahydrofuran, Nitromethane, chloroform, Dichloromethane, Ethyl acetate, or combinations thereof.
[0025] Active agent based renal denervation procedures provide better precision in terms of delivery location and the amount of active agent that need to be delivered. Also, it allows parallel or follow-up administration of medication at the target lesion to treat after-effects of the procedure. In addition, in some embodiments, this administration can be prolonged for a specific time duration. Hence, active agent based renal denervation provides a better alternative to traditional denervation systems to achieve dose-dependent, predictable, safe and essentially painless renal denervation.
[0026] In the above description, for purpose of explanation, specific details are set forth in order to provide an understanding of the present disclosure. It will be apparent, however, to one skilled in the art that the present disclosure may be practiced without these details. One skilled in the art will recognize that embodiments of the present disclosure, one of which is described below, may be incorporated into a number of systems. Further, structures and devices shown in the figures are illustrative of exemplary embodiment of the present disclosure and are meant to avoid obscuring the present disclosure.

DESCRIPTION OF REFERENCE CHARACTER
100 Stent
102 Lumen
104 Outer Periphery
106 Grooves
200 Stent
202 Mesh
204 Lumen
206 Outer Periphery

,CLAIMS:

1. A stent (100) for renal denervation comprising:
a plurality of grooves (106); and
a composition disposed in the grooves (106), the composition having:
at least a polymer;
at least an active agent;
optionally a solvent; and
optionally, an additive,
wherein the ratio of active agent and the polymer in the composition is between 5:95 to 70:30.

2. A stent (200) for renal denervation comprising:
a mesh (202) disposed on outer periphery (206) of the stent (200); and
a composition adapted on the mesh (202), the composition having:
at least a polymer;
at least the active agent;
optionally a solvent; and
optionally, an additive,
wherein the ratio of the active agent and the polymer in the composition is between 5:95 to 70:30.

3. The stent (200) as claimed in claim 2, wherein the mesh (202) is a woven or a non-woven sheet.

4. The stent (200) as claimed in claim 3, wherein the non-woven sheet is made of polymer, non-polymer, cellulose, lignin, natural rubber, sponge or combinations thereof.

5. The stent (200) as claimed in claim 3, wherein the woven sheet is made of a plurality of threads selected from polymeric fibers, non-polymeric fibers, metal wires, alloy wires, synthetic fiber, natural fiber, silk, cotton or combinations thereof.

6. The stent (200) as claimed in claim 3, wherein the active agent is adsorbed and/or absorbed on the mesh or on the threads.

7. The stent (200) as claimed in claim 3, wherein the threads are at least partially made up of the active agent.

8. The stent (100, 200) as claimed in claims 1 to 5, wherein the active agent is selected from one or more of anti-restenosis drugs, Neurolytic agents, Quaternary ammonium salts, Sodium Channel Blockers, Anesthetics, Conductive Fluids, Amino Acids, Amines, Calcium Channel Blockers, neurotoxins, venom, neuromodulators, neurotransmitters, Diuretics, Saline, Hypotonic Fluids, Vasovasorum Constrictors, Neurotransmitter Chemicals, Venom, Sclerosant Agents, Anti-Nerve Growth Agents, Aminosteroids, Neurotoxins, Alcohols, 6-Hydroxydopamine, Acebutolol, Acetic Acid, Acetic Anhydride, Acetyl Chloride, Acetylcholine, Adenosine, Aflatoxins, Ambrisentan, Amiloride, Amiodarone, Amlodipine, Ammonia, Acetylcholinesterase, Anti-Dopamine, Beta-Hydroxylase, Anti-Dopamine Beta-Hydroxylase Immunotoxin, Beta-Hydroxylase Saporin, Argon, Arsenic, Atenolol, Azitoxin, Benazepril, Benzocaine, Bepridil, Betanidine, Betaxolol, Bisoprolol, Bleomycin, Bosentan, Botulinum toxin, Bretylium Tosylate, BuLi, Bungarotoxin, Bupivacaine, Bupranolol hydrochloride, Butanol, calcium hydroxide, Caffeine, Calciceptin, Calcycludin, Capsaicin, Carbamazepine, Carbon Dioxide, Cardiac Glycoside, Caribodotoxin, Carteolol, Carteolol hydrochloride, Catopril, Cetylcholine, Cevacine, Cevadine, Chloroquine, Chlorotoxin, Clonidine, Conotoxin, Curare, Cymarins, Cytochalasin D, Debrisoquine, Decarbamoyl Saxitoxins, Dibucaine, Digitalis, Digitoxins, Digoxins, Diltiazem, Dimethyl Sulfoxide, Diprophylline, Disopyramide, Dobutamine hydrochloride, Domoic Acids, Dopamine hydrochloride, Doxazosin, Doxycycline, Enalapril, Enalaprilat, Encainide, Epinephrin, Esmolol, Ethanol, Ethanolamine Oleate, Ethyl Acetate, Ethyl Chloroformate, Ethyl Iodide, Ethyl Lactate, Ethyl Nitrate, Ethylene glycol, Everolimus, Felodipine, Fimolol, Flecainide, Fosinopril, Furosemide, Glutamate, Glycerin, Glycerol, Guanabenz, Guanacline, Guanadrel, Guanazodine, Guanethidine, Guanethidine Sulfates, Guanfacine, Guanidinium, Guanoclor, Guanoxabenz, Guanoxan, hydrogen peroxide, Helium, Hexane, Hydriodic Acid, Hydrobromic Acid, Hydrochloric Acid, Hypertonic Saline, Indoramin, Isobutanol, Isopropanol, Isopropyl Acetate, Isopropyl Iodide, Isoquinoline, Isradipine, potassium carbonate, Ketanserin, potassium hydride, potassium hydroxide, Labetalol, Lactic Acid, Laureth, Leptocurare, Lidocaine, Lipiodol, Lisinopril, Losartan, Malonic Acid, Malonyl Chloride, Margatoxin, Maurotoxin, Mecamylamine, Methanol, Methyl Acetate, Methyldopa, Metildigoxin, Metirosine, Metoprolol, Metoprolol tartrate, Mexiletine, Minosteroids, Moexipril, Moricizine, Morrhuate Sodium, Moxonidine, Mycophenolic Acid, N-(2-Chloroethyl)-N-Ethyl-2-Bromobenzylamine, Nadolol, sodium hydride, sodium bicarbonate, NaOEt, NaSEt, Neosaxitoxins, ammonium hydroxide, Nicardipine, Nifedipine, Nimodipine, Nitric Acid, Nitric oxide, Nitrogen, Nitrous Acid, N-Methyl-(R)-Sarsolinol, Octopamine hydrochloride, Oleandrins, Ouabin, Oxalic Acid, Oxprenolol hydrochloride, Oxygen, Oxytetracycline, Pachycurare, Paclitaxel, Pargyline, Penbatolol, Peracetic Acid, Perchloric Acid, Phenol, Phentolamine, Pheoxybenzamine, Phosphoric Acid, Phoneutria toxin, Pindolol, Polidocanol, Potassium Chloride, Povidone Iodine, Prazosin, Prazosin hydrochloride, Prazosin Plus Polythiazide, Procainamide, Propafenone, Propanol, Propranolol, Propranolol hydrochloride, Propyl Iodide, Proscillaridin, Pyruvic Acid, Quabains, Quinacrine, Quinapril, Quinidine, Quinine, Ramipril, Relmenidine, Rescinnamine, Reserpine, Resiniferatoxin, Saline, Saxitoxins, Sirolimus, Sitagliptin phosphate, Sitaxentan, slatatoxin, Slototoxin, Sodium Chloride, Sodium Morrhuate, Sodium Tetradecyl Sulfate, Sotalol, Staurosporines, Sulfuric Acid, Talc, Taxol, Terazosin, Tetanus Toxin, Tetracaine, Tetracycline, Tetraethylammonium, Tetrodotoxin, Tocainide, Trichlormethiazide, Trimazosin, Trimethaphan, Tycatoxin, Ubidecarenon, Urapidil, Urea, Vanilloids, Vanilloylzygadenine, Heftoxin, Verapamils, Veratridine, Veratroylzygadenine with saline solution, Vinblastin, Vincristine, Zotarolimus, Zygacine, ß-carboline derivative, ?-conotoxin, Heparinized Saline, Butorakotoshkin, neuromodulators, botulinum oxide or combinations thereof.

9. The stent (100, 200) as claimed in claims 1 to 6, wherein the polymer is selected from a biodegradable polymer, a non-biodegradable polymer or combinations thereof.

10. The stent (100, 200) as claimed in claim 7, wherein the polymer is selected from one or more of poly-L-lactide, poly(hydroxybutyrate), polyorthoesters, poly anhydrides, poly(glycolic acid), poly(glycolide), poly(L-lactic acid), poly(D-lactic acid), poly(D-lactide), poly(caprolactone), poly(trimethylene carbonate), polyester amide, polyesters, polyolefins, polycarbonates, polyoxymethylenes, polyimides, polyethers, their copolymers or terpolymers or a combinations thereof.

11. The stent (100, 200) as claimed in claims 1 to 8, wherein the solvent for the composition is selected from one or more of water, polymeric solvent, non-polymeric solvent, saline, biodegradable polymeric liquid or a mixture thereof.